AbbVie's rapidly expanding Humira successor, SKYRIZI, is already achieving impressive sales growth. This IL-23 inhibitor is set to capture an even greater portion of Humira's diminishing market share with its crucial expansion into treating ulcerative colitis.

AbbVie迅速扩张的Humira继任者SKYRIZI已经实现了令人印象深刻的销售增长。这种IL-23抑制剂将在Humira日益减少的市场份额中占据更大的份额，并将其关键扩展到治疗溃疡性结肠炎。

LAS VEGAS, July 15, 2024 /PRNewswire/ -- Ulcerative colitis is an idiopathic inflammatory bowel disease affecting ~1.5 million patients in the US and with an unknown exact cause. It affects the colonic mucosa and is clinically characterized by diarrhea, stomach discomfort, pain, and hematochezia. The disease's extent varies, affecting either the rectum, the splenic flexure of the left side of the colon, or the whole of the rectum and bowel..

拉斯维加斯，2024年7月15日/PRNewswire/--溃疡性结肠炎是一种特发性炎症性肠病，影响美国约150万患者，确切原因未知。它影响结肠粘膜，临床特征是腹泻，胃不适，疼痛和便血。该疾病的程度各不相同，影响直肠，结肠左侧的脾曲，或整个直肠和肠道。。

As per DelveInsight analysis, the total ulcerative colitis diagnosed prevalent cases in the 7MM comprised approximately 3 million cases in 2023 and are projected to increase by 2034. Per analyst estimates, approximately 60% of cases accounted for moderate to severe cases of ulcerative colitis among the 7MM..

根据DelveInsight分析，2023年，7MM中诊断出的溃疡性结肠炎流行病例总数约为300万例，预计到2034年将增加。据分析师估计，在7MM中，大约60%的病例占溃疡性结肠炎的中度至重度病例。。

The current treatments for ulcerative colitis depend on the severity of the disease and are broadly divided into six classes, comprising conventional therapies, Anti-TNFs, Anti-integrin agents, IL-12/IL-23 dual inhibitors, S1P-receptor modulators, and JAK inhibitors.

目前溃疡性结肠炎的治疗方法取决于疾病的严重程度，大致分为六类，包括常规疗法，抗TNF，抗整合素药物，IL-12/IL-23双重抑制剂，S1P受体调节剂和JAK抑制剂。

The emergence of several mechanisms of action, like LANCL2 protein stimulators, miR-124 enhancers, tumor necrosis factor (TNF)-like ligand 1A inhibitors, toll-like receptor 9 agonists, and others will be expanding the treatment landscape of ulcerative colitis.

几种作用机制的出现，如LANCL2蛋白刺激剂，miR-124增强子，肿瘤坏死因子（TNF）样配体1A抑制剂，toll样受体9激动剂等，将扩大溃疡性结肠炎的治疗范围。

There have been significant advancements in treating ulcerative colitis over the years. However, safety remains a major challenge. The lack of a safer and curative treatment option severely impacts patients' quality of life and daily activities. While current treatments are effective for some patients with ulcerative colitis, others need multiple lines of therapy, indicating a need for alternative treatments to achieve disease control.

多年来，治疗溃疡性结肠炎取得了重大进展。然而，安全仍然是一个重大挑战。缺乏更安全和治愈性的治疗选择严重影响了患者的生活质量和日常活动。虽然目前的治疗方法对一些溃疡性结肠炎患者有效，但其他患者需要多种治疗方法，这表明需要替代治疗来实现疾病控制。

Several major pharmaceutical companies are collaborating to develop new solutions to address these issues..

几家主要制药公司正在合作开发解决这些问题的新解决方案。。

Learn more about the FDA-approved ulcerative colitis drugs @ Drugs for Ulcerative Colitis Treatment

了解更多有关FDA批准的溃疡性结肠炎药物@溃疡性结肠炎治疗药物的信息

A few FDA-approved drugs for ulcerative colitis treatment include SIMPONI (Janssen Pharmaceuticals), ENTYVIO (Takeda Pharmaceuticals), OMVOH (Eli Lilly) VELSIPITY (Arena Pharmaceuticals/Pfizer), and SKYRIZI (AbbVie).

一些FDA批准用于溃疡性结肠炎治疗的药物包括SIMPONI（Janssen Pharmaceuticals），ENTYVIO（Takeda Pharmaceuticals），OMVOH（Eli Lilly）VELSIPITY（Arena Pharmaceuticals/Pfizer）和SKYRIZI（AbbVie）。

SIMPONI is a human monoclonal antibody that targets and neutralizes excess tumor necrosis factor (TNF)-alpha, a protein associated with inflammation and tissue damage in chronic inflammatory diseases. It is the first subcutaneous anti-TNF-alpha treatment administered every four weeks as maintenance therapy for ulcerative colitis.

SIMPONI是一种人类单克隆抗体，可靶向并中和过量的肿瘤坏死因子（TNF）-α，这是一种与慢性炎症性疾病中的炎症和组织损伤相关的蛋白质。这是第一次每四周进行一次皮下抗TNF-α治疗，作为溃疡性结肠炎的维持治疗。

Approved for treating moderately to severely active ulcerative colitis in adults, SIMPONI is also being evaluated in ongoing trials for pediatric patients with the same condition..

SIMPONI被批准用于治疗成人中度至重度活动性溃疡性结肠炎，目前正在对患有相同疾病的儿科患者进行评估。。

Vedolizumab is a humanized monoclonal antibody that targets and inhibits the alpha 4 beta 7 integrin, preventing it from binding to the intestinal mucosal addressing cell adhesion molecule 1 (MAdCAM-1). This integrin is found in a subset of circulating white blood cells that play a role in the inflammatory processes of ulcerative colitis and Crohn's disease.

维多珠单抗是一种人源化单克隆抗体，可靶向并抑制α4β7整联蛋白，阻止其与肠粘膜寻址细胞粘附分子1（MAdCAM-1）结合。这种整合素存在于循环白细胞的一个子集中，这些白细胞在溃疡性结肠炎和克罗恩病的炎症过程中起作用。

By blocking the alpha 4 beta 7 integrin, vedolizumab may reduce the infiltration of these white blood cells into gut tissues..

通过阻断α4β7整合素，维多珠单抗可以减少这些白细胞向肠道组织的浸润。。

It is currently approved as an IV and SC formulation for the treatment of moderately to severely active ulcerative colitis in adults who have not responded to, lost response to, or were intolerant to conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.

它目前被批准为IV和SC制剂，用于治疗对常规治疗或肿瘤坏死因子-α（TNFα）拮抗剂无反应，失去反应或不耐受的成人中度至重度活动性溃疡性结肠炎。

VELSIPITY (Etrasimod) is an innovative, once-daily oral medication that acts as a highly selective modulator of the sphingosine 1-phosphate (S1P) receptor. Discovered by Arena, it is designed for optimized interaction with S1P receptors 1, 4, and 5, potentially offering better efficacy and safety. Etrasimod targets specific immune cells both systemically and locally and has the potential to treat various immune-mediated inflammatory diseases, such as Crohn's disease and ulcerative colitis..

VELSIPITY（Etrasimod）是一种创新的每日一次的口服药物，可作为1-磷酸鞘氨醇（S1P）受体的高选择性调节剂。Arena发现，它旨在与S1P受体1、4和5进行优化相互作用，可能提供更好的疗效和安全性。Etrasimod在全身和局部靶向特定的免疫细胞，并有可能治疗各种免疫介导的炎症性疾病，如克罗恩病和溃疡性结肠炎。。

It is currently approved by the FDA and EMA for adults with moderately to severely active ulcerative colitis who have not responded adequately, lost response, or were intolerant to conventional or advanced therapies.

它目前已被FDA和EMA批准用于中度至重度活动性溃疡性结肠炎的成年人，这些成年人对常规或先进疗法没有充分反应，失去反应或不耐受。

Recently, on 18 June 2024, the FDA approved SKYRIZI for treating adult patients with moderately to severely active ulcerative colitis. This approval extends the drug's reach to approximately 1 million US patients and makes SKYRIZI the first IL-23 inhibitor approved for both UC and Crohn's disease, the two types of inflammatory bowel disease (IBD)..

最近，2024年6月18日，FDA批准SKYRIZI用于治疗中度至重度活动性溃疡性结肠炎的成年患者。这项批准将该药物的范围扩大到约100万美国患者，并使SKYRIZI成为首个被批准用于UC和克罗恩病（两种炎症性肠病（IBD））的IL-23抑制剂。。

After a 12-week induction period, patients can self-administer the medication at home using an on-body injector device, which AbbVie's press release describes as 'designed with patients in mind.' The device attaches to the body and delivers the medication in about five minutes.

经过12周的诱导期后，患者可以在家中使用体内注射装置自行给药，AbbVie的新闻稿称这种装置是“为患者设计的”该装置附着在身体上，大约在五分钟内输送药物。

Since its approval for Crohn's in 2022, Skyrizi has emerged as a strong competitor to Johnson & Johnson's blockbuster drug STELARA in the IBD market. The AbbVie medication has captured a 'significant share' of STELARA's sales.

自2022年批准克罗恩氏病以来，Skyrizi在IBD市场上已成为强生公司重磅药物STELARA的有力竞争对手。AbbVie药物在STELARA的销售额中占据了“相当大的份额”。

To know more about ulcerative colitis treatment options, visit @ New Treatment for Ulcerative Colitis

要了解更多关于溃疡性结肠炎治疗方案的信息，请访问@溃疡性结肠炎新疗法

The ulcerative colitis market is crowded with so many companies including Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck, Mesoblast, and others are running clinical trials to improve the treatment space.

溃疡性结肠炎市场挤满了许多公司，包括Arena Pharmaceuticals，辉瑞（Pfizer），Abivax，Reistone Biopharma，InDex Pharmaceuticals，AbbVie，勃林格殷格翰（Boehringer Ingelheim），Janssen Pharmaceuticals，Landos Biopharma，NImmune，Merck，Mesoblast等公司正在进行临床试验以改善治疗空间。

The ulcerative colitis pipeline possesses potential drugs in mid-stage developments to be launched shortly..

溃疡性结肠炎管道在即将推出的中期开发中拥有潜在的药物。。

Some of the promising drugs in the pipeline include TREMFYA, ABX464, BT-11 (Omilancor), PRA023, Remestemcel-L, SHR0302 (Ivarmacitinib), and others that hold the potential to create a significant positive shift in the ulcerative colitis market size.

正在开发的一些有前途的药物包括TREMFYA，ABX464，BT-11（Omilancor），PRA023，Remestemcel-L，SHR0302（Ivarmacitinib），以及其他有可能在溃疡性结肠炎市场规模上产生重大积极变化的药物。

Discover which therapies are expected to grab major ulcerative colitis market share @ Ulcerative Colitis Market Report

发现哪些疗法有望占据溃疡性结肠炎的主要市场份额@溃疡性结肠炎市场报告

TREMFYA (guselkumab) is a human monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, created by Janssen. IL-23 plays a crucial role in the pathogenesis of inflammatory diseases like ulcerative colitis and Crohn's disease. TREMFYA, an IL-23 inhibitor, is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody, produced in a mammalian cell line using recombinant DNA technology.

TREMFYA（guselkumab）是一种针对Janssen创建的白细胞介素（IL）-23 p19亚基的人单克隆抗体。IL-23在溃疡性结肠炎和克罗恩病等炎症性疾病的发病机制中起着至关重要的作用。TREMFYA是一种IL-23抑制剂，是一种人免疫球蛋白G1λ（IgG1λ）单克隆抗体，使用重组DNA技术在哺乳动物细胞系中产生。

It specifically binds to the p19 subunit of IL-23 and blocks its interaction with the IL-23 receptor..

它特异性结合IL-23的p19亚基并阻断其与IL-23受体的相互作用。。

In May 2024, Johnson & Johnson released the initial data from the Phase III QUASAR maintenance study in ulcerative colitis, which achieved its primary endpoint and all major secondary endpoints, including highly statistically significant rates of endoscopic remission. Based on these findings, the company has submitted a supplemental Biologics License Application (sBLA) to the FDA..

2024年5月，强生公司发布了溃疡性结肠炎III期QUASAR维持研究的初步数据，该研究实现了其主要终点和所有主要次要终点，包括内镜缓解率的高度统计学显着性。根据这些发现，该公司已向FDA提交了补充生物制剂许可证申请（sBLA）。。

SHR0302, developed by Reistone Biopharma, is an innovative and potent oral JAK1 inhibitor aimed at treating inflammatory bowel diseases like ulcerative colitis and Crohn's disease. Due to its selectivity for JAK1, it may offer a safer and more effective alternative to pan-JAK inhibitors. Ongoing long-term clinical studies are investigating whether JAK1 selectivity can minimize hematological side effects associated with JAK2 inhibition, aiming to confirm a favorable risk-benefit profile (Reistone Biopharma, 2021a)..

由Reistone Biopharma开发的SHR0302是一种创新且有效的口服JAK1抑制剂，旨在治疗溃疡性结肠炎和克罗恩病等炎症性肠病。由于其对JAK1的选择性，它可能为泛JAK抑制剂提供更安全，更有效的替代品。正在进行的长期临床研究正在调查JAK1选择性是否可以最大程度地减少与JAK2抑制相关的血液学副作用，旨在确认有利的风险-收益概况（Reistone Biopharma，2021a）。。

SHR0302 is currently being tested in a Phase III clinical trial (NCT05181137) for the treatment of moderate to severe ulcerative colitis in adults.

SHR0302目前正在III期临床试验（NCT05181137）中进行测试，用于治疗成人中重度溃疡性结肠炎。

Discover more about drugs for ulcerative colitis in development @ Ulcerative Colitis Clinical Trials

了解更多有关溃疡性结肠炎药物的开发@溃疡性结肠炎临床试验

The anticipated launch of these emerging therapies for ulcerative colitis are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the ulcerative colitis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth..

预计这些溃疡性结肠炎新兴疗法的推出将在未来几年改变市场格局。随着这些尖端疗法的不断成熟并获得监管部门的批准，预计它们将重塑溃疡性结肠炎的市场格局，为医疗创新和经济增长提供新的护理标准和解锁机会。。

DelveInsight estimates that the market size for ulcerative colitis is expected to grow from USD 8.4 billion in 2023 with a significant CAGR by 2034. This growth can be attributed to the introduction of upcoming therapies and the rising prevalence of the disease. The anticipated launch of these therapies is also expected to attract new entrants to the ulcerative colitis market, resulting in increased competition and innovation..

DelveInsight估计，溃疡性结肠炎的市场规模预计将从2023年的84亿美元增长到2034年的复合年增长率。这种增长可归因于即将推出的疗法和该疾病患病率的上升。预计这些疗法的推出也将吸引新的进入者进入溃疡性结肠炎市场，从而增加竞争和创新。。

DelveInsight's latest published market report titled as Ulcerative Colitis Market Insight, Epidemiology, and Market Forecast – 2034 will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the ulcerative colitis country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential.

DelveInsight最新发布的市场报告《溃疡性结肠炎市场洞察、流行病学和市场预测-2034》将帮助您发现哪个市场领导者将占据最大的市场份额。该报告提供了溃疡性结肠炎国家特定治疗指南，患者库分析和流行病学预测的全面见解，以帮助了解关键机会并评估市场的潜在潜力。

The ulcerative colitis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:.

溃疡性结肠炎市场报告提供了2020-2034年研究期间的流行病学分析，其中7MM分为：。

Total Diagnosed Prevalent Cases of Ulcerative Colitis

溃疡性结肠炎的总诊断流行病例

Age-specific Cases of Ulcerative Colitis

溃疡性结肠炎的年龄特异性病例

Severity-specific Cases of Ulcerative Colitis

溃疡性结肠炎的严重程度特异性病例

Total Treated Patients of Ulcerative Colitis

溃疡性结肠炎患者总数

The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM ulcerative colitis market. Highlights include:

该报告通过了解影响和推动7MM溃疡性结肠炎市场的趋势，在制定商业战略时提供了优势。亮点包括：

11-year Forecast

11年预测

7MM Analysis

7MM分析

Epidemiology-based Market Forecasting

基于流行病学的市场预测

Historical and Forecasted Market Analysis upto 2034

截至2034年的历史和预测市场分析

Emerging Drug Market Uptake

新兴药物市场的吸纳

Peak Sales Analysis

峰值销售分析

Key Cross Competition Analysis

关键交叉竞争分析

Industry Expert's Opinion

行业专家意见

Access and Reimbursement

访问和报销

Download this ulcerative colitis market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the ulcerative colitis market. Also, stay abreast of the mitigating factors to improve your market position in the ulcerative colitis therapeutic space..

下载这份溃疡性结肠炎市场报告，以评估流行病学预测，了解患者旅程，了解KOLs对即将到来的治疗范例的意见，并确定导致溃疡性结肠炎市场转变的因素。此外，了解缓解因素，以提高您在溃疡性结肠炎治疗领域的市场地位。。

Related Reports

相关报告

Ulcerative Colitis Epidemiology Forecast

溃疡性结肠炎流行病学预测

Ulcerative Colitis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted ulcerative colitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

溃疡性结肠炎流行病学预测-2032年报告提供了对该疾病的深入了解，以及7MM的历史和预测溃疡性结肠炎流行病学，即美国，EU5（德国，西班牙，意大利，法国和英国）和日本。

Ulcerative Colitis Pipeline

溃疡性结肠炎管道

Ulcerative Colitis Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ulcerative colitis companies, including Eli Lilly and Company, Lipid Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, InDex Pharmaceuticals, EA Pharma, Theravance Biopharma, Boehringer Ingelheim, Janssen Research & Development, Lycera, LG Chem, Iltoo Pharma, Immunic, Hutchison Medipharma, Tianjin Hemay Pharmaceutical, GlaxoSmithKline, Galapagos, Celgene, Gossamer Bio, Eisai, UCB, Suzhou Connect Biopharmaceuticals, Landos Biopharma, Seres Therapeutics, Abivax, Genentech, ParaTech A/S, I-Mab Biopharma, Sublimity Therapeutics Holdco, Reistone Biopharma, Qu Biologics, PurGenesis Technologies, Protagonist Therapeutics, Pfizer, Palobiofarma, Novartis Pharmaceuticals, Bristol-Myers Squibb, Bridge Biotherapeutics, Amgen, Allergan, Applied Molecular Transport, AbGenomics International, Protalix BioTherapeutics, LTT Bio-Pharma Co Ltd, Dongwha pharma, Seres Therapeutics, Innovation Pharmaceuticals, Holy Stone Healthcare, SLA Pharma, OSE Immunotherapeutics, Bridge Biotherapeutics, Mitsubishi Tanabe Pharma, Sterna Biologicals, Mesoblast, Oncostellae, First Wave Bio, Oppilan Pharma, NeuClone, Morphic Therapeutic, Metacrine, LG Chem, Koutif Therapeutics, Kiniksa Pharmaceuticals, Avaxia Biologics, Algernon Pharmaceuticals, Akeso Biopharma, Kaleido Biosciences, Rebiotix, Prometheus Biosciences, PNB Vesper Life Science, Pandion Therapeutics, Palatin Technologies, Theravance Biopharma, VHsquared, Seres Therapeutics, Hoffmann-La Roche, Provention Bio, Bacainn Therapeutics, Landos Biopharma, Bristol-Myers Squibb, Janssen Research & Development, GlaxoSmithKline, Assembly Biosciences, NuBi.

溃疡性结肠炎管道洞察-2024年报告提供了有关管道景观、管道药物概况（包括临床和非临床阶段产品）以及关键溃疡性结肠炎公司（包括礼来公司、脂质治疗公司、霍夫曼·拉罗氏、竞技场制药、指数制药、EA制药、Theravance Biopharma、勃林格殷格翰、詹森研发、Lycera、LG Chem、Iltoo Pharma、Immunic、和记医药、天津赫美制药、葛兰素史克、加拉帕戈斯、Celgene、Gossamer Bio、Eisai、UCB、苏州Connect Biopharmaceuticals等）的全面见解。Landos Biopharma，Seres Therapeutics，Abivax，Genentech，ParaTech A/S，I-Mab Biopharma，Sublimity Therapeutics Holdco，Reistone Biopharma，Qu Biologics，PurGenesis Technologies，Protation Therapeutics，辉瑞，Palobiofarma，诺华制药，百时美施贵宝，Bridge Biotherapeutics，Amgen，Allergan，Applied Molecular Transport，AbGenomics International，Protalix BioTherapeutics，LTT Bio Pharma Co Ltd，Dongwha Pharma，Seres Therapeutics，Innovation Pharmaceutics，Holy Stone Healthcare，SLA Pharma，OSE Immunotherapeutics，Bridge BioTherapeutics，Mitsubishi Tanabe Pharma，Sterna Biologicals，Mesoblast，Oncostellae，First Wave Bio，Oppilan Pharma，NeuClone，Morphic Therapeutics，Metacrine，LG Chem，Koutif Therapeutics，Kiniksa Pharmaceuticals，Avaxia Biologics，Algernon Pharmaceuticals，Akeso Biopharma Technologies、Theravance Biopharma、VHsquared、Seres Therapeutics、Hoffmann La Roche、Provention Bio、Bacainn Therapeutics、Landos Biopharma、Bristol-Myers Squibb、Janssen Research＆Development、GlaxoSmithKline、Assembly Biosciences、NuBi。

Crohn's Disease Market

克罗恩病市场

Crohn's Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Crohn's disease companies, including Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Amgen, Priothera, SLA Pharma, HAV Vaccines Ltd, Enzo Biochem Inc., VHsquared Ltd., among others..

克罗恩病市场洞察、流行病学和市场预测-2034年报告深入了解了克罗恩病、历史和预测流行病学，以及市场趋势、市场驱动因素、市场障碍和主要克罗恩病公司，包括Celgene、AstraZeneca、Abbvie、Mesoblast、Alfasigma、Tiziana Life Sciences、Abivax、Arena Pharmaceuticals、Cytocom、Amgen、Priothera、SLA Pharma、HAV Vaccines Ltd、Enzo Biochem Inc.和VHsquared Ltd.等。。

Irritable Bowel Syndrome Market

肠易激综合征市场

Irritable Bowel Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key irritable bowel syndrome companies, including Arena Pharmaceuticals, 4D Pharma, OrphoMed, Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, Synthetic Biologics, Biomica, among others..

肠易激综合征市场洞察、流行病学和市场预测-2034年报告深入了解了市场趋势、市场驱动因素、市场障碍和主要肠易激综合征公司，包括Arena Pharmaceuticals、4D Pharma、OrphoMed、Boston Pharmaceuticals、RedHill Biopharma Limited、Takeda、Cosmo Technologies、CinRx Pharma、Rottapharm、Synthetic Biologics、Biomica等。。

About DelveInsight

关于DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve..

DelveInsight是一家专注于生命科学的领先商业顾问和市场研究公司。它通过提供全面的端到端解决方案来提高制药公司的绩效，从而为制药公司提供支持。通过我们基于订阅的平台PharmDelve，轻松访问所有医疗保健和制药市场研究报告。。

Contact UsShruti Thakur info@delveinsight.com +14699457679

联系Usshruti Thakurinfo@delveinsight.com+14699457679

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

标志：https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP

来源：DelveInsight Business Research，LLP